Mind-NRG
Stage
Series B | AliveTotal Raised
$10MLast Raised
$8M | 9 yrs agoAbout Mind-NRG
Mind-NRG is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood-brain barrier through a receptor-mediated transport to reach its target in the brain. NRG-101 is being developed to treat disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia.
Mind-NRG Headquarter Location
Rue de Jargonnant 2
Geneva, CH-1207,
Switzerland
+41 22 737 00 00
Mind-NRG Patents
Mind-NRG has filed 7 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Neurological disorders
- Proteins
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/23/2019 | 10/27/2020 | Clusters of differentiation, Neurological disorders, Transcription factors, Rare diseases, Proteins | Grant |
Application Date | 5/23/2019 |
|---|---|
Grant Date | 10/27/2020 |
Title | |
Related Topics | Clusters of differentiation, Neurological disorders, Transcription factors, Rare diseases, Proteins |
Status | Grant |
Latest Mind-NRG News
Sep 4, 2013
By FinSMEs Mind-NRG , a Geneva, Switzerland-based company focusing on developing neuregulins to treat neurodegenerative diseases, closed its €6m (approximately $8m) Series B financing. Backers included new investor LRM and existing investor Index Ventures . Following the investment, Debora Dumont, Head of Health & Care at LRM will join the company’s board of directors. Created in 2010, Mind-NRG is investigating the use of neuregulins in treating a variety of neurological and psychiatric disorders. In particular, it is developing NRG-101 to treat the early-stages of neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease, as well as schizophrenia. The company plans to use the funding to continue to develop NRG-101’s neuroprotective effect in Parkinson’s disease, with the aim of advancing the compound to proof-of-concept studies in patients. FinSMEs
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.